Menu Search
Equities

DOD Biotech PCL

DOD:SET

DOD Biotech PCL

Actions
  • Price (THB)3.12
  • Today's Change0.08 / 2.63%
  • Shares traded1.95m
  • 1 Year change-23.90%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in THBIncome statement in THBView more

Year on year DOD Biotech PCL grew revenues 26.25% from 537.16m to 678.15m while net income improved from a loss of 398.33m to a gain of 7.19m.
Gross margin33.50%
Net profit margin-23.07%
Operating margin-18.86%
Return on assets-12.45%
Return on equity-14.24%
Return on investment-15.58%
More ▼

Cash flow in THBView more

In 2023, DOD Biotech PCL increased its cash reserves by 124.62%, or 37.72m. Cash Flow from Financing totalled 104.72m or 15.44% of revenues. In addition the company generated 22.80m in cash from operations while cash used for investing totalled 89.79m.
Cash flow per share-0.2098
Price/Cash flow per share--
Book value per share1.97
Tangible book value per share1.87
More ▼

Balance sheet in THBView more

DOD Biotech PCL has a Debt to Total Capital ratio of 13.94%, a higher figure than the previous year's 5.27%.
Current ratio1.95
Quick ratio1.47
Total debt/total equity0.1598
Total debt/total capital0.1394
More ▼

Growth rates in THB

Year on year, growth in earnings per share excluding extraordinary items increased 105.37%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
EPS growth(5 years)-44.42
EPS (TTM) vs
TTM 1 year ago		65.57
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.